MIRA PHARMACEUTICALS, INC.
Business
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and addiction-related disorders. Lead programs include Ketamir-2 (NMDA receptor modulator for neuropathic pain), MIRA-55 (cannabinoid analog for inflammatory pain and CNS conditions), and SKNY-1 (dual CB1/CB2 and MAO-B modulator for obesity and nicotine dependence). MIRA holds exclusive North American rights to all programs and contracts manufacturing with third parties.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Revenues | — | — | — | — | |
| General and administrative expenses | 9 | 5 | 6 | 3 | |
| Research and development expenses | 2 | 3 | 2 | 2 | |
| Total operating costs | 10 | 8 | 9 | 7 | |
| Interest income | 98,911 | 165,669 | — | — | |
| Other expense | −13,072 | — | — | — | |
| Unrealized loss on short-term investment | −35,212 | — | — | — | |
| Total other income, net | 50,627 | 165,669 | — | — | |
| Net Loss | −10 | −8 | −12 | −7 | |
| Deemed dividend | −22 | — | — | — | |
| Net loss attributable to common stockholders | −32 | −8 | — | — | |
| Basic loss per share | −1.35 | −0.51 | −0.85 | −0.4 | |
| Diluted loss per share | −1.35 | −0.51 | −0.85 | −0.4 | |
| Basic weighted average common stock shares outstanding | 24 | 15 | 14 | 18 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-04-30 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash | 6 | 3 | — | — | — | |
| Prepaid expenses | 28,146 | 54,729 | — | 243,802 | — | |
| Short-term investment, at fair value related party | 5 | — | — | — | — | |
| Total current assets | 11 | 3 | — | 5 | 494,405 | |
| Total assets | 11 | 3 | — | 5 | 858,074 | |
| Trade accounts payable and accrued liabilities | 129,203 | 723,349 | — | — | — | |
| Due to related party | 572,865 | — | — | — | — | |
| Total current liabilities | 702,068 | 723,349 | — | 558,097 | 1 | |
| Total liabilities | 702,068 | 723,349 | — | 558,097 | 1 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized and none issued or outstanding. | — | — | — | — | — | |
| Common Stock, $0.0001 par value; 100,000,000 shares authorized, 41,938,587 and 16,560,852 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively. | 4,194 | 1,656 | — | 1,478 | 6,657 | |
| Additional paid-in capital | 50 | 31 | 148,703 | 26 | 9 | |
| Accumulated deficit | −40 | −29 | — | −21 | −9 | |
| Total stockholders equity | 10 | 2 | — | 4 | −596,232 | |
| Total liabilities and stockholders equity | 11 | 3 | — | 5 | 858,074 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Stock-based compensation expense | 6 | 2 | 3 | 1 | |
| Prepaid expenses | 26,583 | 189,073 | −243,802 | — | |
| Other receivables | — | 11,862 | −11,862 | — | |
| Trade accounts payable and accrued expenses | −594,146 | 184,785 | −389,524 | 152,081 | |
| Related party accrued interest | — | −14,472 | — | — | |
| Net cash used in operating activities | −5 | −6 | −5 | −6 | |
| Offering costs | −292,470 | — | 143,427 | −43,427 | |
| Proceeds from related party | 572,865 | — | — | — | |
| Proceeds from Common stock option exercises | 888,282 | — | — | — | |
| Advances from (to) affiliates | — | 33,713 | — | — | |
| Bayshore Trust short-swing disgorgement | — | 148,703 | — | — | |
| Proceeds from sale of common stock | 7 | 4 | 8 | 3 | |
| Net cash provided by financing activities | 8 | 4 | 9 | 3 | |
| Net increase (decrease) in cash | 4 | −2 | 4 | −2 | |
| Cash paid for interest | — | — | — | — | |
| Cash paid for income taxes | — | — | — | — | |
| Deferred offering costs charged to additional paid-in capital | — | 32,500 | 426,345 | — | |
| Issuance of common stock for the short-term investments, SKNY acquisition | 5 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is MIRA PHARMACEUTICALS, INC.'s CIK number?
MIRA PHARMACEUTICALS, INC.'s SEC CIK number is 0001904286 (1904286). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find MIRA PHARMACEUTICALS, INC.'s SEC filings?
All of MIRA PHARMACEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.